Damian McNamara is a journalist for Medscape Medical News and MDedge. He worked full-time for MDedge as the Miami Bureau covering a dozen medical specialties during 2001-2012, then as a freelancer for Medscape and MDedge, before being hired on staff by Medscape in 2018. Now the two companies are one. He uses what he learned in school – Damian has a BS in chemistry and an MS in science, health and environmental reporting/journalism. He works out of a home office in Miami, with a 100-pound chocolate lab known to snore under his desk during work hours.
News
Study highlights need to investigate psoriasis treatment outcomes in skin of color patients
MIAMI – Researchers used phase 2 and 3 psoriasis clinical trial data to explore potential differences in treatment response in various ethnic...
News
Alemtuzumab-induced autoimmunity: getting closer to answers
Researchers are getting closer to identifying MS patients more susceptible to secondary autoimmunity after alemtuzumab treatment.
News
Researchers find predictors of worse MS outcomes in post hoc study of three trials
Predicting which people with MS might experience relapse or progression of disability could help clinicians more closely follow those at higher...
News
Fingolimod switch from an injectable linked to improved outcomes in relapsing MS
SAN DIEGO – The benefit of the switch was observed regardless of previous treatment status.
Aesthetic Dermatology
Set realistic expectations prior to perioral rejuvenation procedures
MIAMI – For major perioral lines, an “orange peel” texture, and/or elastotic changes, laser resurfacing can be an appropriate option.
News
Be alert for BAP1 mutations in hereditary melanomas
MIAMI – They’re rare genetic mutations that can make melanoma more aggressive and lethal, as well as signal of a potentially elevated risk for...
Video
VIDEO: Managing the alemtuzumab paradox
SAN DIEGO – Dr. Alasdair Coles explains the best management approach for this “high risk, high gain” drug.
News
Third course of alemtuzumab can improve MS outcomes
SAN DIEGO – Patients who experience radiographic relapse after two courses of alemtuzumab may not be treatment failures.
Video
VIDEO: New MS ambulatory measure could fill clinical gap
SAN DIEGO – Dr. Emily Evans explains how the single-item instruments measure up to existing ambulatory scales.
Video
VIDEO: Alemtuzumab associated with long-term MS control in TOPAZ study
SAN DIEGO – Extension study reveals durable benefit at 7 years.
Video
VIDEO: Could targeting gut dysbiosis in MS prevent disease?
SAN DIEGO – Transgenic mouse studies lead to questions of altering gut flora to prevent disease in people at high risk for multiple sclerosis.
News
Fingolimod cuts pediatric MS relapse rate more than interferon beta-1a
The PARADIGMS study is the first international controlled trial to test fingolimod in pediatric patients.
News
Want to expand aesthetic dermatology business? Appeal to men
Bringing in more male patients to an aesthetic dermatology practice can deliver a long-term payoff in loyalty and return business.
News
Best practices address latest trends in PDT, skin cancer treatment
MIAMI – Consider new CPT codes for PDT and the benefit of hedgehog inhibitors to shrink some skin cancers before further treatment.
News
Five pearls target wound healing
MIAMI – Recent evidence in the literature counters conventional wisdom on wound closure, and provides other clinical tips to foster better wound...